Entera Bio Ltd. EBITDA 2011-2026 | ENTX

Earnings before Interest, Taxes, Depreciation, and Amortization (EBITDA), is an often used measure of a company's profitability. Financial analysts use EBITDA for a number of purposes including calculating simple valuations of a firm, estimating cash flows, and assessing debt servicing capability. The uses for EBITDA in financial analysis are numerous, but in practice should be more restrained. While EBITDA has some useful applications, it should be used with caution, as the problems with EBITDA are abundant and can lead to a number of misguided conclusions.^[1]

EBITDA is an important indicator for investors and analysts because it allows them to evaluate a company's operating profit without considering the impact of financial expenses, taxes, or non-cash depreciation and amortization. It provides better comparability between companies in different industries or with different tax conditions.

EBITDA is often used to assess a company's ability to generate cash flow and repay debts. It can also serve as a measure of a company's operational efficiency, as it shows how profitable the core business is, regardless of external factors such as interest or taxes.

However, it is important to note that EBITDA is not an official financial statement measure and can be defined and calculated differently by companies. Therefore, investors and analysts should exercise caution when using EBITDA as an evaluation tool and combine it with other financial metrics and information to get a more complete picture of a company's financial condition.

Annual EBITDA Entera Bio Ltd.

2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
-	-11.1 M	-11.5 M	-10.9 M	-11.3 M	-5.33 M	-3.67 M	-	-	-	-

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
-3.67 M	-11.5 M	-8.97 M

Quarterly EBITDA Entera Bio Ltd.

2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
-	-	-	-	-	-	-2.65 M	-	-	-	-3.53 M	-	-	-	-2.03 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
-2.03 M	-3.53 M	-2.74 M

References

Brockman, C. M., & Russell, J. W. (2012). EBITDA: use it... or lose it?. International Journal of Business, Accounting and Finance, 6(2), 84-93.

EBITDA of other stocks in the Biotechnology industry

Issuer	EBITDA	Price	% 24h	Market Cap	Country
MorphoSys AG MOR	-508 M	-	2.43 %	$ 254 M	Germany
Advaxis ADXS	-35.9 M	-	-9.65 %	$ 45.9 M	USA
Akouos AKUS	-84.3 M	-	0.23 %	$ 488 M	USA
Allakos ALLK	-190 M	-	-	$ 28.6 M	USA
AlloVir ALVR	-46.1 M	-	4.14 %	$ 49.1 M	USA
I-Mab IMAB	13.8 M	-	-	$ 866 M	China
Aeglea BioTherapeutics AGLE	-242 M	-	-	$ 1.01 B	USA
Ampio Pharmaceuticals AMPE	122 K	-	-11.43 %	$ 502 K	USA
Midatech Pharma plc MTP	-7 M	-	-18.52 %	$ 27.3 M	Britain
Alexion Pharmaceuticals, Inc. ALXN	3.11 B	-	-	$ 40.3 B	USA
Applied Molecular Transport AMTI	-124 M	-	-	$ 10.1 M	USA
Applied Therapeutics APLT	-64.5 M	-	-	$ 8.42 M	USA
Aptorum Group Limited APM	1.19 M	$ 0.88	-2.05 %	$ 6.47 M	China
Biophytis SA BPTS	-26.8 M	-	-13.47 %	$ 169 M	France
Genfit SA GNFT	31.8 M	-	2.54 %	$ 160 B	France
ACADIA Pharmaceuticals ACAD	232 M	$ 22.46	0.72 %	$ 3.72 B	USA
Aptinyx APTX	-62.4 M	-	-39.0 %	$ 4.57 M	USA
EyeGate Pharmaceuticals, Inc. EYEG	-8.18 M	-	-1.52 %	$ 24.7 M	USA
Ayala Pharmaceuticals AYLA	-37.3 M	-	-	$ 7.46 M	Israel
Brainstorm Cell Therapeutics BCLI	-9.75 M	-	-2.5 %	$ 5.88 M	USA
BioDelivery Sciences International BDSI	37.3 M	-	-4.8 %	$ 255 M	USA
AIkido Pharma AIKI	-55.6 M	-	1.93 %	$ 17.4 M	USA
Cara Therapeutics CARA	-26.7 M	-	-3.03 %	$ 260 M	USA
CASI Pharmaceuticals CASI	-41.4 M	-	-	$ 35.4 M	USA
Институт стволовых клеток человека ISKJ	220 M	-	-	-	Russia
ChromaDex Corporation CDXC	16.9 M	-	-0.88 %	$ 598 M	USA
Aeterna Zentaris AEZS	-8.67 M	-	5.93 %	$ 314 M	Canada
Galectin Therapeutics GALT	-20.1 M	$ 2.32	-2.32 %	$ 148 M	USA
AgeX Therapeutics AGE	-23.9 M	-	-10.17 %	$ 12.2 K	USA
Aravive ARAV	-70 M	-	-13.39 %	$ 1.45 M	USA
Genmab A/S GMAB	6.57 B	$ 26.78	0.53 %	$ 16.8 B	Danmark
Aridis Pharmaceuticals ARDS	-29.5 M	-	17.91 %	$ 11.1 M	USA
BioNTech SE BNTX	15.3 B	$ 100.91	-1.13 %	$ 27.2 B	Germany
Checkpoint Therapeutics CKPT	-56.2 M	-	-	$ 169 M	USA
Avenue Therapeutics ATXI	-3.08 M	-	-52.27 %	$ 4.45 M	USA
Applied Genetic Technologies Corporation AGTC	-16.2 M	-	-	$ 26.5 M	USA
Aquestive Therapeutics AQST	-70.5 M	$ 4.08	-0.61 %	$ 436 M	USA
Arcutis Biotherapeutics ARQT	-11.5 M	$ 23.06	-1.54 %	$ 2.93 B	USA
Heron Therapeutics HRTX	-224 K	$ 1.22	2.1 %	$ 203 M	USA
ImmuCell Corporation ICCC	4.43 M	$ 8.34	1.07 %	$ 75.3 M	USA
Autolus Therapeutics plc AUTL	-262 M	$ 1.49	4.58 %	$ 397 M	Britain
Aptose Biosciences APTO	22 K	-	-45.71 %	$ 1.2 M	Canada
AstraZeneca PLC AZN	1.06 B	-	-	$ 96.9 B	Britain
AVROBIO AVRO	10.8 M	-	1083.1 %	$ 745 M	USA
Innate Pharma S.A. IPHA	-47.8 M	$ 1.41	0.71 %	$ 235 M	France
Can-Fite BioPharma Ltd. CANF	-9.93 M	$ 2.92	-0.14 %	$ 4.81 M	Israel
Inventiva S.A. IVA	-52.1 M	$ 5.04	-1.75 %	$ 138 M	France
BeiGene, Ltd. BGNE	589 M	-	0.49 %	$ 251 B	Cayman-islands
Akero Therapeutics AKRO	-285 M	-	-	$ 3.67 B	USA
bluebird bio BLUE	-216 M	-	-	$ 546 M	USA